Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
Johnson & Johnson(JNJ) stock is priced at $235.37, giving the company a market capitalization of 567.8B. It carries a P/E multiple of 21.54 and pays a dividend yield of 2.2%.
During the trading session on 2026-03-20, Johnson & Johnson(JNJ) shares reached a daily high of $238.29 and a low of $234.50. At a current price of $235.37, the stock is +0.4% higher than the low and still -1.2% under the high.
Trading volume for Johnson & Johnson(JNJ) stock has reached 17.16M, versus its average volume of 7.25M.
The stock's 52-week range extends from a low of $141.50 to a high of $251.71.
The stock's 52-week range extends from a low of $141.50 to a high of $251.71.
JNJ News
Shares of AbbVie ABBV fell 5.2% on Wednesday, wiping out more than $20 billion in market value. This selloff comes as investors grow wary of Johnson & Johnson’s...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for moderate-to-severe p...
Barclays raised the firm’s price target on Johnson & Johnson to $234 from $217 and keeps an Equal Weight rating on the shares. The firm says its analysis confir...
Analyst ratings
59%
of 29 ratingsMore JNJ News
On 18 March 2026, Johnson & Johnson received U.S. FDA approval for ICOTYDE (icotrokinra), the first targeted oral IL-23 receptor antagonist for moderate-to-seve...
Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling sh...
Protagonist Therapeutics (PTGX) announced that Johnson & Johnson (JNJ) received FDA approval for ICOTYDE, or icotrokinra, an interleukin-23 receptor antagonist...
Johnson & Johnson (JNJ) on Wednesday announced that the U.S. Food and Drug Administration (FDA) approved Icotyde, a once-daily pill developed with Protagonist T...
Johnson & Johnson announced that the U.S. Food and Drug Administration, FDA, has approved Icotyde, an interleukin-23 receptor antagonist for the treatment of mo...
Johnson & Johnson (JNJ) is back in focus after recent trading, with the stock closing at US$238.11. Investors are weighing this move against its month and past...
A California judge has overturned a jury’s decision ordering Johnson & Johnson to pay nearly $1B in punitive damages to the family of a woman who died from meso...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.